Comparative Pharmacology
Head-to-head clinical analysis: FLOVENT DISKUS 50 versus HYDROCORTONE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FLOVENT DISKUS 50 versus HYDROCORTONE.
FLOVENT DISKUS 50 vs HYDROCORTONE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Glucocorticoid receptor agonist; anti-inflammatory transcription factor modulation; inhibits phospholipase A2, reduces arachidonic acid release, decreases prostaglandin and leukotriene synthesis; suppresses cytokine production and inflammatory cell migration.
Hydrocortisone is a corticosteroid that binds to the glucocorticoid receptor, leading to anti-inflammatory and immunosuppressive effects by inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis, and suppressing cytokine production.
1 inhalation (50 mcg) twice daily, administered via oral inhalation.
100-500 mg intravenously every 2-6 hours for initial management of adrenal insufficiency; oral maintenance: 20-30 mg daily in divided doses (e.g., 10 mg morning, 5 mg afternoon).
None Documented
None Documented
Terminal elimination half-life is approximately 14-17.5 hours; this supports once- or twice-daily dosing in asthma maintenance.
Terminal elimination half-life: 1.5–2.5 hours (plasma), but biological half-life (duration of HPA axis suppression) is 8–12 hours.
Primarily fecal (87-90%) after hepatic metabolism; renal excretion accounts for <5% as unchanged drug and metabolites.
Renal (primarily as inactive metabolites; <5% unchanged) and biliary/fecal (minor).
Category C
Category C
Corticosteroid
Corticosteroid